Results 131 to 140 of about 24,654 (177)
Exploring the potential of vamotinib in Ph+ leukemias: is it indeed a 3rd generation tyrosine kinase-inhibitor? [PDF]
Lucini C +4 more
europepmc +1 more source
A case report of BCR-ABL(+) acute myeloid leukemia and literature review. [PDF]
Li J, Zheng W, Dong X, Wang J, Liu K.
europepmc +1 more source
Case Report: Chronic myeloid leukemia masquerading as essential thrombocythemia in a child: the imperative for early BCR::ABL1 testing in isolated thrombocytosis. [PDF]
He H, Fu J.
europepmc +1 more source
Determinants of Abl kinase stability and drug binding thermodynamics: Role of regulatory domains and phosphorylation. [PDF]
Juárez-Barragán A +5 more
europepmc +1 more source
openaire +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Model Mice for BCR/ABL-Positive Leukemias
Blood Cells, Molecules, and Diseases, 2001p210bcr/abl is detected in almost all chronic myelogenous leukemia (CML) patients and a significant number of acute lymphoblastic leukemia (ALL) cases. It is generated by a reciprocal chromosomal translocation, t(9;22) (q34;q11), and the enhanced kinase activity of the protein is believed to be implicated in the pathogenesis of the diseases. To examine
H, Honda, H, Hirai
openaire +2 more sources
Current and future management of Ph/BCR-ABL positive ALL
Expert Review of Anticancer Therapy, 2014Following the introduction of targeted therapy with tyrosine kinase inhibitors (TKI) at the beginning of the past decade, the outcome of patients with Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) has dramatically improved. Presently, the use of refined programs with first/second generation TKI's and chemotherapy together with
Elena, Maino +6 more
openaire +2 more sources
Management of Bcr–Abl-positive leukemias with dasatinib
Expert Review of Anticancer Therapy, 2007Dasatinib is a novel, potent, multi-targeted kinase inhibitor that is approved in Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) and Ph+ acute lymphoblastic leukemia following imatinib failure. Clinical trials have demonstrated its activity across all phases of CML. Dasatinib was superior to high-dose imatinib in a randomized,
openaire +2 more sources
Mechanisms of resistance to imatinib mesylate in Bcr-Abl–positive leukemias
Current Opinion in Oncology, 2002The constitutive activity of the Bcr-Abl tyrosine kinase plays a critical role in the molecular pathogenesis of not only the chronic but also the accelerated and blastic phases of chronic myelogenous leukemia. Therefore, Bcr-Abl tyrosine kinase is a rational therapeutic target in all phases of chronic myelogenous leukemia.
Ramadevi, Nimmanapalli, Kapil, Bhalla
openaire +2 more sources

